Provided by Tiger Trade Technology Pte. Ltd.

Organon & Co

13.68
+0.01500.11%
Volume:316.43K
Turnover:4.32M
Market Cap:3.59B
PE:17.25
High:13.68
Open:13.67
Low:13.66
Close:13.66
52wk High:13.79
52wk Low:5.69
Shares:262.60M
Float Shares:243.00M
Volume Ratio:0.53
T/O Rate:0.13%
Dividend:0.08
Dividend Rate:0.59%
EPS(TTM):0.7929
EPS(LYR):0.7200
ROE:24.04%
ROA:5.67%
PB:3.57
PE(LYR):18.99

Loading ...

Press Release: Organon to Report Second Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Dow Jones
·
Jul 16

Organon to Present New Pooled Phase 3 Analysis of VTAMA in Atopic Dermatitis at 2026 Pediatric Dermatology Meeting

Reuters
·
Jul 07

Jefferies Quarterly Profit Misses Estimates as Asset Management Weighs

Reuters
·
Jun 25

Jefferies Quarterly Profit More than Doubles on Dealmaking, Equities Strength

Reuters
·
Jun 25

Organon, Shanghai Henlius Biotech Launch Denosumab Biosimilars in Canada

MT Newswires Live
·
Jun 23

Organon Closes Deal to License Sebela Pharmaceuticals' Miudella Intrauterine Device

MT Newswires Live
·
Jun 22

Organon completes global MIUDELLA copper IUD licensing deal with Sebela

Reuters
·
Jun 22

Organon Completes Agreement to License Miudella®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device

THOMSON REUTERS
·
Jun 22

Organon & Co - Miudella Expected to Be Commercially Available in Late 2026

THOMSON REUTERS
·
Jun 22

Organon and Samsung Bioepis expand commercialization agreement for Pyzchiva

TIPRANKS
·
Jun 18

Organon, Samsung Bioepis expand Canada commercialization pact for ustekinumab biosimilar PYZCHIVA

Reuters
·
Jun 18

Organon & Co - Pyzchiva Expected to Launch in Canada in 2026

THOMSON REUTERS
·
Jun 18

Organon & Co - Agreement Expands Biosimilar Collaboration in Canada to Six Products

THOMSON REUTERS
·
Jun 18

Organon & Co - to Obtain Commercialization Rights to Pyzchiva in Canada

THOMSON REUTERS
·
Jun 18

Organon and Samsung Bioepis Expand Agreement to Commercialize Pyzchiva® (Ustekinumab), a Biosimilar Referencing Stelara® (Ustekinumab) in Canada

THOMSON REUTERS
·
Jun 18

Shore Capital Reaffirms Their Buy Rating on Origin Enterprises plc (OGN)

TIPRANKS
·
Jun 17

Organon shareholders approve amended 2021 incentive stock plan, adding 8 million shares

Reuters
·
Jun 12

Organon wins US approval to widen use of arthritis biosimilar drug

Reuters
·
Jun 10

Organon Expands Tofidence Label With FDA Approval for Additional Indications

MT Newswires Live
·
Jun 10

Organon announces U.S. FDA approval pf sBLA for Tofidence injection

TIPRANKS
·
Jun 10